Overview
- 24 inspections across 22 sites are on record.
- 11 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2023-03-21.
At a glance
Inspections
24
Sites
22
Observations
11
Career since
Dec 2014
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Octapharma Produktionsgesellschaft Deutschland mbH | 21 Mar 2023 | Biologics | On file |
| Biomarin Pharmaceutical Inc. | 9 Dec 2022 | Biologics | On file |
| FinVector Oy | 27 Sep 2022 | Biologics | On file |
| Pfizer Manufacturing Belgium NV | 2 Jul 2021 | Biologics | |
| FinVector Oy | 28 Jan 2020 | Biologics | On file |
Sites inspected
Octapharma Produktionsgesellschaft Deutschland mbHSpringe, Germany1 insp.
Biomarin Pharmaceutical Inc.Novato, United States1 insp.
FinVector OyKuopio, Finland2 insp.
Pfizer Manufacturing Belgium NVPuurs-Sint-Amands, Belgium1 insp.
Co-investigators
Investigators who share inspections with this person.
Yonggang Wang2 shared
Susan M Jackson2 shared
Maria J Lopez- Barragan2 shared
Bo Chi2 shared
Zhihao Pete Qiu2 shared
Zainab Y Mansaray-Storms1 shared
Kula N Jha1 shared
Emmanuel Adu-Gyamfi1 shared
Andrew W Harmon1 shared
Jared D Greenleaf1 shared
Full investigator report
Get the verbatim findings behind Laura Fontan's 11 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site